Cancer Biological Therapy Market Analysis

Cancer Biological Therapy Market Analysis

Cancer biological therapy market valuation from blood cell growth factors (BCGF) is estimated to surpass USD 50 billion by 2032 due to the growing concerns associated with the side effects of cancer treatments. BCGF is increasingly administered in cancer patients to improve their immunity and combat adverse effects such as lower white blood cell count caused by therapies. It helps reduce the risk of infections and potentially boost chemotherapy output by preventing any delay in the procedure. Half of the world’s cancer patients at some point suffer from chemotherapy-induced severe neutropenia, a condition referring to very low WBCs. The growing prevalence of neutropenia as a result of radiation therapy, immunotherapy, stem cell transplant, and cancer itself will also foster the product demand.
 

Cancer biological therapy market size from the oral segment is projected to depict over 6.5% CAGR between 2023-2032. This is attributed to the surging demand for affordable cancer treatments. Oral treatments have a high preference among patients as well as physicians over injectables as they eliminate several unfavorable side effects, such as soreness at the site of injections, and fever or chills.
 

Oral drugs are easy to administer and do not require doctor’s assistance. The presence of extensive R&D initiatives and clinical trials pertaining to FDA-approved therapeutics will complement the segment development.
 

Europe cancer biological therapy market size is slated to reach over USD 55.5 billion by 2032 driven by the rising cases of cancer and the growing geriatric population in the region. According to the European Commission’s Joint Research Center (JRC), the number of individuals diagnosed with cancer is estimated to increase by nearly 18% in 2040 led by the rising geriatric patient pool. Belgium, the Netherlands, Ireland, and Denmark are some of the major hotspots with high cancer prevalence representing lucrative demand for biological therapies. In recent years, Europe has also experienced an upsurge in cancer rates among children.